It is concluded that by inhibiting the release of CGRP in the TRPV1-CGRP/CGRP-R signaling pathway in the trigeminal neurovascular system of migraine, it can provide a new strategy for migraine treatment. This evidence concerns the gene CALCRL and migraine disorder.